Geode Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-18,677
Closed -$13.6K 4734
2023
Q4
$13.6K Hold
18,677
﹤0.01% 4563
2023
Q3
$22.2K Buy
18,677
+7,508
+67% +$9.34K ﹤0.01% 4606
2023
Q2
$15.2K Hold
11,169
﹤0.01% 4688
2023
Q1
$11.8K Hold
11,169
﹤0.01% 4759
2022
Q4
$26K Hold
11,169
﹤0.01% 4731
2022
Q3
$47K Buy
11,169
+123
+1% +$673 ﹤0.01% 4781
2022
Q2
$44K Buy
11,046
+1
+0% +$5 ﹤0.01% 4805
2022
Q1
$95K Hold
11,045
﹤0.01% 4680
2021
Q4
$126K Hold
11,045
﹤0.01% 4652
2021
Q3
$192K Hold
11,045
﹤0.01% 4467
2021
Q2
$205K Buy
11,045
+3,577
+48% +$68.1K ﹤0.01% 4337
2021
Q1
$185K Buy
7,468
+5,705
+324% +$171K ﹤0.01% 4137
2020
Q4
$35K Buy
+1,763
New +$34.5K ﹤0.01% 4215
2020
Q1
Sell
-13
Closed -$2K 4283
2019
Q4
$2K Hold
13
﹤0.01% 4207
2019
Q3
$5K Hold
13
﹤0.01% 4192
2019
Q2
$7K Hold
13
﹤0.01% 4198
2019
Q1
$15K Hold
13
﹤0.01% 4111
2018
Q4
$15K Hold
13
﹤0.01% 4116
2018
Q3
$20K Hold
13
﹤0.01% 4095
2018
Q2
$17K Buy
13
+4
+44% +$21.9K ﹤0.01% 4043
2018
Q1
$93K Hold
9
﹤0.01% 3861
2017
Q4
$133K Sell
9
-1
-10% -$23.1K ﹤0.01% 3762
2017
Q3
$265K Hold
10
﹤0.01% 3577
2017
Q2
$485K Sell
10
-3
-23% -$164K ﹤0.01% 3364
2017
Q1
$956K Buy
13
+1
+8% +$80.8K ﹤0.01% 3040
2016
Q4
$960K Hold
12
﹤0.01% 3009
2016
Q3
$1.48M Buy
12
+1
+9% +$125K ﹤0.01% 2731
2016
Q2
$1.16M Hold
11
﹤0.01% 2818
2016
Q1
$1.39K Buy
11
+2
+22% +$215K ﹤0.01% 2697
2015
Q4
$1.2M Hold
9
﹤0.01% 2804
2015
Q3
$1.43M Buy
+9
New +$2.1M ﹤0.01% 2657

Other funds holding NVIV

Geode Capital Management's NVIV Position: Q1 2024 in Review

Geode Capital Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 18,677 shares — an estimated $13.6K sold.

Geode Capital Management first reported a position in NVIV in Q3 2015 and held it in 31 quarters. The position peaked at $1.48M in Q3 2016. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.

  • Geode Capital Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
  • Geode Capital Management sold 18,677 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $13.6K.
  • Geode Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q3 2015 and held it in 31 quarters.
  • Geode Capital Management's InVivo Therapeutics Holdings Corp position peaked at $1.48M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.

Based on Geode Capital Management's 13F filing for Q1 2024, filed 13 May 2024.